TABLE.

Demographic and Neuropathological Data From the 95 Cases Studied

Case	Gender	Age	NFT Stage	Aβ Phase	APOE	AGD	TDP-43	HS
1	Female	34	I	0	3/4	0	0	0
2	Female	55	I	0	3/3	0	0	0
3	Male	58	I	1	3/4	0	0	0
4	Male	60	I	1	3/3	0	0	0
5	Male	61	I	0	3/3	0	0	0
6	Female	65	I	0	3/4	0	0	0
7	Male	69	I	0	3/3	0	0	0
8	Male	82	I	0	3/4	0	0	0
9	Male	37	II	0	3/3	0	0	0
10	Female	48	II	0	3/3	0	0	0
11	Male	53	II	0	3/4	0	0	+
12	Female	56	II	0	3/4	0	0	0
13	Male	56	II	0	3/3	0	0	0
14	Male	56	II	0	3/3	0	0	0
15	Male	61	II	0	3/3	0	0	0
16	Male	61	II	0	3/3	0	0	0
17	Male	62	II	0	3/3	0	0	0
18	Female	62	II	0	3/3	0	0	0
19	Male	62	II	0	3/3	0	0	0
20	Male	62	II	2	3/4	0	0	0
21	Female	63	II	0	2/3	0	0	0
22	Male	64	II	0	3/3	0	0	0
23	Male	64	II	0	3/3	0	0	+
24	Male	64	II	1	3/4	0	0	0
25	Male	65	II	0	3/3	0	0	0
26	Female	82	II	1	3/3	0	0	0
27	Male	85	II	0	2/3	0	0	0
28	Female	86	II	2	3/3	0	0	0
29	Female	87	II	0	3/3	0	0	0
30	Male	87	II	2	3/4	0	0	0
31	Male	52	III	0	3/3	0	0	0
32	Male	55	III	1	3/4	0	0	0
33	Female	58	III	0	3/3	0	+	0
34	Male	66	III	0	2/3	0	0	+++
35	Female	67	III	0	3/4	0	0	0
36	Female	68	III	3	3/4	0	0	0
37	Female	68	III	1	3/4	0	0	0
38	Female	68	III	2	3/4	0	0	0
39	Male	69	III	0	2/3	0	0	+
40	Female	69	III	5	4/4	0	0	0
41	Female	70	III	0	3/3	0	0	0
42	Male	71	III	0	3/3	0	0	+
43	Male	71	III	3	4/4	0	0	0
44	Female	76	III	1	3/3	0	0	0
45	Female	83	III	0	3/4	0	0	0
46	Female	86	III	3	3/4	0	0	0
47	Female	87	III	0	3/4	0	0	0
48	Female	88	III	0	2/3	0	0	0
49	Female	88	III	0	3/3	0	0	+
50	Male	89	III	0	3/3	0	0	0
51	Female	89	III	0	3/3	0	+++	+++
52	Male	91	III	0	3/3	0	0	+
53	Male	93	III	0	3/3	0	0	0
54	Male	71	IV	3	3/3	0	0	0
55	Male	72	IV	2	3/3	0	0	0
56	Female	75	IV	5	4/4	0	0	0
57	Female	78	IV	3	3/4	0	0	0
58	Male	83	IV	3	3/3	0	0	0
59	Female	84	IV	2	3/4	0	0	0
60	Female	84	IV	2	4/4	0	0	++
61	Female	86	IV	3	3/3	0	0	0
62	Female	86	IV	3	3/4	0	+++	+
63	Female	89	IV	3	3/3	0	0	0
64	Male	90	IV	3	3/4	0	0	0
65	Female	55	V	5	3/3	0	0	0
66	Male	58	V	2	3/4	0	0	0
67	Female	72	V	4	3/3	0	0	0
68	Female	73	V	5	3/3	0	0	0
69	Female	75	V	2	4/4	0	0	0
70	Female	76	V	4	3/4	0	0	0
71	Female	78	V	4	3/3	0	+++	+
72	Female	78	V	0	3/3	0	0	++
73	Female	78	V	3	3/3	0	0	0
74	Male	78	V	5	3/4	0	0	+
75	Male	80	V	2	3/3	0	0	0
76	Female	81	V	4	3/3	0	0	0
77	Female	82	V	3	3/3	0	+	0
78	Male	82	V	4	3/3	0	0	0
79	Male	84	V	3	3/4	0	++	0
80	Female	85	V	3	3/4	0	0	+
81	Female	87	V	4	2/4	0	+++	0
82	Female	88	V	3	3/3	0	0	0
83	Female	88	V	5	3/3	0	0	0
84	Male	88	V	3	2/2	0	0	0
85	Male	88	V	4	2/3	0	0	0
86	Male	89	V	3	3/3	0	0	0
87	Female	89	V	4	3/3	0	++	0
88	Female	90	V	2	3/3	0	0	0
89	Female	92	V	4	3/3	0	0	0
90	Male	93	V	2	3/4	0	0	+++
91	Female	96	V	5	3/3	0	0	0
92	Female	97	V	3	3/3	0	0	0
93	Male	75	VI	4	3/3	0	0	0
94	Female	83	VI	3	3/4	0	+++	+
95	Female	85	VI	4	3/4	0	++	+

The cohort consisted of 52 females and 43 males (age range 34–97 ± 13.1 years of age; mean age 74.5 years).

Its composition reflects the fact that early neurofibrillary changes corresponding to NFT stages I–II are already present in the third and fourth decades of life. NFT stages and Aβ phases increase with age. The disease process underlying sporadic AD develops over a period of decades (11).

NFT, neurofibrillary tangle stages I–VI; Aβ, amyloid-β deposition phases 0–5; AGD, argyrophilic grain disease; HS, hippocampal sclerosis.